Given that elevated IgG1 has been associated with chronic low-grade systemic inflammation and a higher risk of developing macrovascular and microvascular complications, particularly diabetic nephropathy and cardiovascular disease (CVD) [39,44,66], this selective modulation may represent a beneficial immunological effect of CCL3 treatment. The gene discussed is CCL3; the disease is diabetic kidney disease.